Sunday 12 July 2020
Home      All news      Contact us     
reuters - 1 month ago

Gilead s remdesivir could see $7 billion in annual sales on stockpiling boost: analyst

Gilead Sciences Inc s potential COVID-19 treatment, remdesivir, could bring in more than $7 billion in annual sales by 2022, spurred by governments stockpiling the drug to guard against future outbreaks, SVB Leerink said on Wednesday.


Latest News
Hashtags:   

Gilead

 | 

remdesivir

 | 

could

 | 

billion

 | 

annual

 | 

sales

 | 

stockpiling

 | 

boost

 | 

analyst

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources